David Einhorn Gain Therapeutics, Inc. Transaction History
Greenlight Capital Inc
- $1.97 Billion
- Q4 2023
A detailed history of David Einhorn (Greenlight Capital Inc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Greenlight Capital Inc holds 588,410 shares of GANX stock, worth $1.3 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
588,410
Previous 546,560
7.66%
Holding current value
$1.3 Million
Previous $2.45 Million
21.41%
% of portfolio
0.1%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
31Shares Held
3.75MCall Options Held
0Put Options Held
0-
Timelo Investment Management Inc.605KShares$1.34 Million0.45% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.25 Million0.04% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL450KShares$994,5000.0% of portfolio
-
Hohimer Wealth Management, LLC330KShares$729,3000.1% of portfolio
-
Geode Capital Management, LLC Boston, MA184KShares$406,0560.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $26.3M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...